Ryvu Therapeutics, a clinical-stage oncology drug discovery and development company headquartered in Krakow, Poland, and listed on the Warsaw Stock Exchange (WSE: RVU), has launched Keelira, a dedicated business unit offering early clinical development services to biotech and pharma companies seeking to extend oncology programmes into Europe.
Cambridge-based CN Bio, a provider of organ-on-a-chip systems for drug discovery and development, has been awarded £180k in grant funding from Innovate UK to support the development of new approach methodologies for pharmacokinetic studies. The funding is being delivered in partnership with the National Centre for the Replacement, Refinement and Reduction of Animals in Research […]
FairJourney Bio (FJBio), an antibody discovery organisation with operations in Porto, Portugal, and Cambridge, UK, has contributed to a peer-reviewed study published in the journal mAbs describing a dual-specificity antibody fragment designed to activate the cytokine IL-12 selectively within the tumour microenvironment.
Carterra®, a provider of high-throughput surface plasmon resonance (HT-SPR) instrumentation for antibody and small-molecule characterisation, has featured in one of the largest published wet-lab validations of AI-generated proteins to date. In a study released on 18 August 2026, Anthropic reported that its Claude models had autonomously run de novo protein binder design campaigns against 15 […]
ENPICOM, a ‘s-Hertogenbosch, Netherlands-based bioinformatics and AI company focused on biologics discovery and development, has been selected by Evolved Therapeutics to support data analysis across the biotechnology company’s antibody discovery programmes. The agreement covers next-generation sequencing (NGS) data analysis and clone selection, two stages of the discovery process that typically demand substantial bioinformatics resource.
Toxys, a contract research organisation CRO) specialising in animal-free toxicology, has announced a strategic collaboration with Mutagentech, a biotechnology company focused on advanced genomic technologies, to bring single-molecule mutation sequencing (SMM-seq) to pharmaceutical, chemical and consumer product developers.
ProBioGen and Transgene have extended their existing collaboration through an additional licence agreement covering ProBioGen’s AGE1.CR.pIX® suspension cell line, a platform used in the manufacture of viral vaccines and immunotherapies.
An international consortium has published details of a large collection of next-generation, patient-derived cancer models in Nature, giving laboratories worldwide new tools with which to study tumour biology and screen for therapeutic targets.
Vancomycin, long a last line of defence against hospital superbugs, is losing its power as resistant bacteria spread. Now researchers have found a small molecule that can restore its punch against vancomycin-resistant Enterococcus faecium, offering a fresh route to tackling one of medicine’s most stubborn antimicrobial resistance problems.
A Madison-based team has stripped liquid chromatography out of peptide mapping, the workhorse test drug developers use to check whether antibody therapeutics have degraded. The new method, described in a bioRxiv preprint and now spun out as the company CeleramAb, promises to turn a nine-day analysis into a matter of hours.